Investor relations

With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.

We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.

Johan Spetz

CFO and Head of Investor Relations

ir@sedanamedical.com Send Email

The Share

See More

Press Releases

Sedana Medical receives market approval in Italy

Non-regulatory

Sedana Medical AB (publ) has received market approval for Sedaconda[®] (isoflurane) for inhaled seda…

Invitation to presentation of Sedana Medical’s fourth quarter and Year-End Report 2022

Non-regulatory

Sedana Medical AB (publ) plans to present its fourth quarter and Year-End Report for 2022 in an audi…

First day of trading in Sedana Medical’s shares on Nasdaq Stockholm

Regulatory

Sedana Medical AB (publ) (the "Company" or "Sedana Medical") announced on 19 January 2023 that Nasda…

View All Press Releases

Financial Calendar

Year-End Report 2022 16 February 2023 07:00
Annual Report 2022 03 April 2023 07:00

See More